Top Page
Boston Scientific
(NYSE:BSX)
Boston Scientific (BSX) vs. SPDR S&P 500 ETF (SPY)
Boston Scientific Business Overview & Revenue Model
Boston Scientific Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Main Street DataBoston Scientific Earnings Call Summary
Boston Scientific Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.49B | 16.75B | 14.24B | 12.68B | 11.89B | 9.91B |
| Gross Profit | 11.69B | 10.27B | 8.83B | 7.71B | 7.46B | 5.58B |
| EBITDA | 4.71B | 3.94B | 3.45B | 2.74B | 2.52B | 1.51B |
| Net Income | 2.50B | 1.85B | 1.59B | 698.00M | 1.04B | -82.00M |
Balance Sheet | ||||||
| Total Assets | 41.56B | 39.40B | 35.14B | 32.47B | 32.23B | 30.78B |
| Cash, Cash Equivalents and Short-Term Investments | 534.00M | 414.00M | 865.00M | 928.00M | 1.93B | 1.73B |
| Total Debt | 12.03B | 11.15B | 9.49B | 9.28B | 9.45B | 9.54B |
| Total Liabilities | 18.91B | 17.39B | 15.61B | 14.90B | 15.61B | 15.45B |
| Stockholders Equity | 22.42B | 21.77B | 19.28B | 17.57B | 16.62B | 15.33B |
Cash Flow | ||||||
| Free Cash Flow | 3.31B | 2.65B | 1.70B | 914.00M | 1.32B | 1.13B |
| Operating Cash Flow | 4.29B | 3.44B | 2.50B | 1.53B | 1.87B | 1.51B |
| Investing Cash Flow | -6.76B | -5.69B | -2.57B | -2.01B | -1.60B | -411.00M |
| Financing Cash Flow | 114.00M | 1.81B | 5.00M | -548.00M | -95.00M | 293.00M |
Boston Scientific Technical Analysis
Boston Scientific Risk Analysis
Boston Scientific Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $148.27B | 53.50 | 12.66% | ― | 21.62% | 54.80% | |
79 Outperform | $48.39B | 35.79 | 13.59% | ― | 0.19% | 65.58% | |
77 Outperform | $219.72B | 15.85 | 30.62% | 1.87% | 6.37% | 142.39% | |
71 Outperform | $118.26B | 25.46 | 9.72% | 3.04% | 4.98% | 22.08% | |
70 Outperform | $136.15B | 46.75 | 14.04% | 0.95% | 10.95% | -18.32% | |
69 Neutral | $21.45B | 30.61 | 30.63% | ― | 14.21% | 5.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Boston Scientific Corporate Events
Boston Scientific is spearheading a new clinical study titled ‘Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss.’ The study aims to evaluate the long-term weight loss outcomes for patients who underwent ESG more than five years ago. This research is significant as it seeks to provide insights into the durability of ESG as a weight loss solution, potentially influencing treatment approaches for obesity and related conditions.
Study Overview: Boston Scientific is conducting a study titled ‘SpaceIT Hydrogel System for Perirectal Spacing in Subjects With Low to Intermediate Risk Prostate Cancer Undergoing External Beam Radiotherapy (EBRT).’ The study aims to evaluate the safety and effectiveness of the SpaceIT Hydrogel System in reducing radiation exposure to the anterior rectum during prostate cancer treatment, highlighting its potential significance in improving patient outcomes.
Study Overview: The FRONTIER study, officially titled ‘A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM,’ is spearheaded by Boston Scientific. This study aims to assess the safety and technical feasibility of the TheraSphere GBM device in treating patients with recurrent glioblastoma, a highly aggressive brain cancer. The significance of this study lies in its potential to offer a novel therapeutic option for a condition with limited treatment alternatives.
Study Overview: The ReMATCH Study, officially titled ‘Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System,’ is a prospective, single-arm, open-label, multi-center study. It aims to evaluate the efficacy of the FARAPULSE PFA System in treating persistent atrial fibrillation, a condition characterized by irregular heartbeats. This study is significant as it explores an innovative approach to managing a common cardiac arrhythmia.
Boston Scientific’s ELEGANCE Registry, officially titled ‘Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature,’ aims to gather real-world data on the use of drug-eluting devices for treating peripheral vascular disease. This study is significant as it includes populations previously underrepresented in similar trials and focuses on health economics and safety.
Study Overview: The clinical study titled IT Matters: The Erectile Restoration Registry aims to gather real-world data on the safety and efficacy of Boston Scientific’s penile prostheses. This observational study is significant as it seeks to enhance understanding of these devices’ performance in treating erectile dysfunction, a condition affecting many men worldwide.
Boston Scientific is currently recruiting for its clinical study titled AGENT DCB STANCE: AGENT Drug-Coated Balloon for STent AvoidANCE in PCI for De Novo Coronary Artery Disease. The study aims to evaluate the safety and effectiveness of the AGENT Drug-Coated Balloon (DCB) compared to the standard percutaneous coronary intervention (PCI) treatment using drug-eluting stents (DES) and/or balloon angioplasty for patients with de novo coronary lesions. This study is significant as it explores alternative treatment strategies that could potentially reduce the need for stent implantation.
Boston Scientific is spearheading a new clinical study titled Prospective, Randomized Clinical Study Evaluating Transoral Outlet Reduction (TORe) and Lifestyle Modification for Patients With Weight Regain Following Roux-en-Y Gastric Bypass. The study aims to assess the effectiveness of TORe combined with lifestyle changes versus lifestyle changes alone in individuals experiencing weight regain after gastric bypass surgery. This research is significant as it explores potential solutions for a common issue faced by patients post-surgery.
Boston Scientific is currently conducting the Stone and Laser Therapies Post-Market Study (SALT) to gather post-market safety and performance data on its devices used in urinary tract procedures and benign prostatic hyperplasia (BPH) treatments. This study is significant as it aims to ensure the continued safety and efficacy of these devices in real-world settings.
Study Overview: Boston Scientific is conducting a study titled ‘A Prospective Multi-Center, Single-Arm Study of Endoscopic Ultrasound-Guided Gastroenterostomy With Lumen-Apposing Metal Stent for Gastric Outlet Obstruction From Malignant Unresectable Disease.’ The study aims to evaluate the safety and technical success of using the AXIOS™ lumen-apposing Metal Stent to manage symptoms of gastric outlet obstruction caused by malignant, unresectable neoplasms.
Boston Scientific is spearheading a new clinical study titled A Prospective Multicenter Trial Evaluating the Safety and Effectiveness of Endo-SPONGE for the Treatment of Anastomotic or Hartmann’s Stump Leakages in the Lower Pelvic Area. The study aims to assess the safety and effectiveness of the Endo-SPONGE device, a sponge-based endoscopic vacuum therapy (EVT), in treating anastomotic leaks and Hartmann’s stump leakages following colorectal surgery. This research is significant as it addresses complications that can arise post-surgery, potentially improving patient outcomes.
Boston Scientific is currently recruiting for a study titled ‘Deep Brain Stimulation (DBS) Retrospective Outcomes Study.’ The primary aim is to assess real-world clinical outcomes of DBS by reviewing de-identified patient records. This study is significant as it focuses on understanding the effectiveness of DBS in treating conditions like Parkinson’s Disease, Essential Tremor, and Dystonia.
Study Overview: The Patient Retrospective Outcomes (PRO) study, conducted by Boston Scientific, aims to evaluate anonymous data from medical charts to assess the clinical outcomes of various treatment approaches for chronic pain. This study is significant as it seeks to enhance understanding of treatment efficacy, potentially guiding future therapeutic strategies.
The SIMPLAAFY Clinical Trial, officially titled ‘WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device With Alternative Post-Implant Monotherapy,’ aims to evaluate the safety and effectiveness of two monotherapy regimens compared to dual antiplatelet therapy (DAPT) following the implantation of the WATCHMAN FLX Pro device. This study is significant as it addresses treatment options for patients with atrial fibrillation, stroke, and bleeding risks.
Boston Scientific is conducting a study titled ‘A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain.’ The study aims to assess the real-world clinical outcomes, economic value, and technical performance of its neurostimulation systems for pain management. This research is significant as it evaluates the long-term effectiveness of these systems in routine clinical practice.
Boston Scientific has announced a new clinical study titled Evaluation of Endoscopic Sleeve Gastroplasty (ESG) as an Alternative Weight Loss Strategy for Patients With Obesity Discontinuing GLP-1 Receptor Agonists Due to Intolerance or Ineffectiveness: A Retrospective Study. The study aims to assess the weight loss outcomes and safety of ESG compared to lifestyle modifications in patients with obesity who have stopped GLP-1 therapy due to intolerance or insufficient weight loss. This study is significant as it explores alternative weight loss strategies for a growing demographic.
Study Overview: The Vercise DBS Registry, officially titled ‘Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry,’ aims to gather global data on the outcomes of using Boston Scientific’s Vercise DBS System for treating Parkinson’s disease. This study evaluates the effectiveness of Image Guided Programming (IGP) and the DBS Illumina 3D feature in enhancing patient treatment.
Study Overview: The clinical study titled ‘A DirEct to PatieNt Study in Chronic Pain’ aims to gather real-world data directly from patients experiencing chronic pain who have received or are planning to receive a commercially approved interventional medical device therapy. The study is significant as it seeks to understand the outcomes and metrics associated with these therapies in routine clinical practice.
The MOSAIC Study, officially titled ‘Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control,’ is a clinical trial conducted by Boston Scientific. The study aims to evaluate the effectiveness of time variant pulse spinal cord stimulation (TVP-SCS) in patients suffering from chronic pain, specifically targeting those with intractable low back and leg pain. This research is significant as it seeks to compile real-world clinical outcomes, potentially offering new hope for individuals with chronic pain conditions.
Boston Scientific is conducting a study titled ‘Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure.’ The study aims to compare two heart pacing methods for treating heart failure: the standard Cardiac Resynchronization Therapy (CRT) and the experimental Left Bundle Branch Area Pacing (LBBAP). This research is significant as it may redefine treatment protocols for heart failure patients.
Boston Scientific has initiated a study titled ‘Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area – Post-Market Clinical Follow-up (SEPTA PMCF).’ The study aims to evaluate the long-term safety, performance, and clinical benefits of using the INGEVITY+ pacemaker lead in patients with bradycardia who require a pacemaker. This research is significant as it seeks to provide insights into the effectiveness of this specific pacing method, potentially influencing future treatment protocols.
Study Overview: Boston Scientific is conducting a study titled ‘EkoSonic Endovascular System in China RWS (ANTEATER)’ to gather real-world clinical outcome data on the EkoSonic Endovascular System in Chinese patients with acute pulmonary embolism. The study aims to assess the system’s effectiveness in practical clinical settings, highlighting its significance in improving patient care for this serious condition.
Boston Scientific is conducting a study titled ‘Safety and Effectiveness of Orbera365™ Intragastric Balloon System: A Multi-Center, Prospective, Standard of Care Registry.’ The study aims to evaluate the safety and effectiveness of the Orbera365™ Intragastric Balloon (IGB) System for weight loss in subjects within the EU. This registry is significant as it provides insights into the real-world application of the device in managing obesity.
Study Overview: The POLARx Post Approval Study (POLARx PAS) is a prospective multi-site study aimed at evaluating the safety and effectiveness of Boston Scientific’s Cardiac Cryoablation System. This study focuses on patients with drug-refractory, recurrent symptomatic paroxysmal atrial fibrillation (AF), assessing the procedural success of pulmonary vein isolation (PVI) using the POLARx/POLARx Fit catheters.
Boston Scientific has initiated a clinical study titled ‘Real World Data Collection in Chinese Population Treated With the FARAPULSE™ Pulsed Field Ablation System’. The study aims to gather real-world data on the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) system, specifically in treating Paroxysmal Atrial Fibrillation (AF) within the Chinese population. This research is significant as it seeks to validate the system’s performance in a real-world setting, potentially influencing future treatment protocols and regulatory approvals.
Boston Scientific is currently conducting the SOCRATES study, officially titled ‘BoStOn SCientific Rhythm MAnagemenT REgiStry.’ This observational study aims to gather comprehensive data on the quality, performance, and safety of Boston Scientific’s cardiac rhythm management (CRM) devices over their entire lifecycle. The study is part of a post-market surveillance system required by regulations such as the EU Medical Device Regulation, ensuring the ongoing evaluation of medical devices.
Study Overview: Boston Scientific is conducting a clinical study titled ‘Clinical Study to Evaluate the Safety and Efficacy of the Orbera365 Intragastric Balloon System in Obese Patients.’ The study aims to assess the safety and effectiveness of the Orbera365 device in aiding weight loss in obese individuals, which is significant for expanding treatment options in obesity management.
Study Overview: The study titled ‘Feasibility Study of the FARAFLEX Mapping and Pulsed Field Ablation (PFA) System in the Treatment of Persistent Atrial Fibrillation’ aims to assess the safety and effectiveness of the FARAFLEX mapping and PFA catheter. This novel device targets persistent atrial fibrillation (PersAF) and symptomatic Paroxysmal Atrial Fibrillation (PAF), conditions that significantly impact cardiovascular health.
Boston Scientific is conducting the RHAPSODY study, officially titled ‘RHythmia mAPping and Signal acquisitiOn for Data analYsis.’ The study aims to evaluate new software features in the Rhythmia Mapping System used for catheter-based endocardial mapping in patients with atrial or ventricular tachyarrhythmias. The insights gained will guide future software development, enhancing the system’s capabilities.
Boston Scientific is conducting a study titled ‘A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation.’ The study aims to evaluate the acute and long-term safety and effectiveness of the FARAPULSE Pulsed Field Ablation System in treating atrial fibrillation. It also seeks to understand the relationship between various procedural factors and outcomes.
Boston Scientific is currently conducting the FARAPULSE Workflow Assessment Registry, a study aimed at optimizing procedural workflows for the ablation treatment of Atrial Fibrillation (AF). The study seeks to identify best practices by analyzing various workflow-related variables such as pre-procedural imaging and anesthesia techniques, using the FARAPULSE™ Pulsed Field Ablation System in a standard care setting. The significance of this study lies in its potential to enhance patient outcomes by tailoring procedures based on patient demographics and cardiac characteristics.
Boston Scientific is conducting a clinical study titled ‘French Prospective Study on Biliary Tract Drainage Guided by Endoscopic Ultrasound in Patients With Malignant Biliary Stenosis (RAINBOW).’ The study aims to evaluate the effectiveness of the Hot AXIOS™ stent in improving the quality of life for patients with malignant biliary stenosis who require bile duct drainage after ERCP failure. This research is significant as it could offer a new treatment avenue for patients facing this challenging condition.
Boston Scientific is currently conducting a study titled ‘A Prospective, Multi-center Study to Evaluate Efficacy and Safety of BSJ020R in Treatment of AVF for Hemodialysis’ (RANGER AV Japan Study). The primary aim is to assess the efficacy and safety of the RANGER™ Paclitaxel Coated Balloon in treating arteriovenous fistula (AVF) stenosis, a condition crucial for patients undergoing hemodialysis. This study is significant as it could potentially improve vascular access for dialysis patients, enhancing their quality of life.
Boston Scientific is currently conducting a study titled ‘cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia’ (OPTION-A), aimed at evaluating the effectiveness of a combined procedure for patients with atrial fibrillation. This study is significant as it explores a novel approach to treating AF by integrating the FARAPULSE™ Pulsed Field Ablation (PFA) system with the WATCHMAN Left Atrial Appendage Closure (LAAC) device, potentially offering a more efficient treatment option.
The ADVENT LTO Study, officially titled ‘ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression,’ is an observational study conducted by Boston Scientific. The primary aim is to assess the progression of atrial fibrillation in patients who have undergone ablation treatment using either the FARAPULSE Pulsed Field Ablation System or thermal ablation. This study is significant as it seeks to provide long-term insights into the effectiveness of these treatments in managing paroxysmal atrial fibrillation.
Boston Scientific is conducting a study titled ‘Boston Scientific Registry of Deep Brain Stimulations for Treatment of Essential Tremor (ET): ET Registry.’ The study aims to gather real-world data on the outcomes of their Deep Brain Stimulation (DBS) Systems for treating Essential Tremor, a common movement disorder. This research is significant as it seeks to validate the effectiveness of DBS systems in practical settings, potentially enhancing treatment protocols for patients.
Boston Scientific is currently conducting a study titled ‘Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System – RAPID for CNS.’ The study aims to gather real-world outcomes of their RF ablation systems used in the central nervous system for functional neurosurgery, focusing on conditions like Parkinson’s Disease, Dystonia, Essential Tremor, and other movement disorders. This research is significant as it seeks to validate the effectiveness of these systems in a clinical setting.
Study Overview: The Vercise™ DBS Dystonia Prospective Study, officially titled ‘Prospective Study of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia,’ aims to gather real-world outcome data on Boston Scientific’s Vercise™ Deep Brain Stimulation systems for treating dystonia. This study is significant as it seeks to validate the effectiveness of this intervention in a real-world setting, potentially influencing treatment protocols and patient care.
Boston Scientific is currently conducting a clinical study titled Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain. The study aims to compile real-world outcomes of the Intracept™ Intraosseous Nerve Ablation Systems in treating patients with vertebrogenic pain. This study is significant as it seeks to provide evidence on the effectiveness of this minimally invasive procedure in managing chronic low-back pain.
Boston Scientific is currently recruiting participants for a clinical study titled ‘Linear Ablation Added to Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Pulsed Field Ablation for Persistent Atrial Fibrillation: a Multi-center Randomized Controlled Trial’. The study aims to determine if adding linear ablation to pulmonary vein isolation (PVI) using pulsed field ablation (PFA) is more effective in maintaining sinus rhythm in patients with persistent atrial fibrillation compared to PVI alone.
Boston Scientific has announced a new clinical study titled ‘Intravascular Ultrasound Guidance for Complex High-risk Indicated Procedures in Underrepresented Patient Populations Registry’ (IVUS CHIP UPP Registry). The study aims to evaluate the effectiveness of intravascular ultrasound (IVUS) guidance in percutaneous coronary intervention (PCI) for complex coronary artery disease, particularly in patients traditionally underrepresented in clinical trials. This research is significant as it seeks to improve treatment outcomes for diverse patient populations.
Boston Scientific’s recent earnings call showcased a robust positive sentiment, highlighting significant sales and EPS growth. The company’s success was largely attributed to key products like WATCHMAN and EP, although challenges were noted in the EMEA region and certain product lines due to operational disruptions and market-specific headwinds.
On October 22, 2025, John E. Sununu announced he will not seek re-election to Boston Scientific‘s Board of Directors at the 2026 Annual Meeting. Sununu, who has been a board member since 2009, will continue his roles until then, with his decision not stemming from any disagreement with the company. The board will assess the need for new directors following his departure.
The most recent analyst rating on (BSX) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Boston Scientific is a global leader in medical technology, providing innovative solutions that address complex health conditions across various medical fields including cardiovascular, respiratory, and neurological diseases.
On August 29, 2025, Boston Scientific announced that Jeffrey B. Mirviss will retire from his position as Executive Vice President and President of Peripheral Interventions, effective December 1, 2025. He will continue as a senior advisor until February 27, 2026, receiving a prorated base salary. The company plans to enter into a Retirement Agreement with Mr. Mirviss, ensuring he receives benefits consistent with the company’s Executive Retirement Plan and other incentive programs.
The most recent analyst rating on (BSX) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.